Atherothrombosis

This website is intended exclusively for healthcare professionals residing and/or working in Bahrain.

Atherothrombosis

Discover more on science updates, events, KOLs interviews and more on Atherothrombosis

Science in Atherothrombosis

Get a 360º view and stay up-to-date on Atherothrombosis with content selected for you

In hospital outcomes in young patients with AMI: Results from Gulf Coast

Adherence and persistence analysis in patients treated with DAPT

Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?

Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)

Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice

SEE EVERYTHING

Inspiration and innovation

Get inspired and stay at the forefront of innovation with the following resources

Understanding de-escalation in antiplatelet therapy

Single antiplatelet therapy Insights on earlier use

Management of antithrombotic therapy in patients with AF undergoing PCI

Clopidogrel as the standard of care for elective PCI: Findings from the ALPHEUS

SEE EVERYTHING

YOU WILL NOW BE LEAVING THE SITE

By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.

Continue

This website is intended exclusively for healthcare professionals residing and/or working in Bahrain.

Please choose if you are a healthcare professional and wish to continue on this site or if you are a member of the public to be redirected to the Sanofi website.